Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.

被引：0
|
作者：
Besse, Benjamin
Mazieres, Julien
Ribassin-Majed, Laureen
Barlesi, Fabrice
Bennouna, Jaafar
Gervais, Radj
Moreau, Lionel
Berard, Henri
Debieuvre, Didier
Molinier, Oliver
Moro-Sibilot, Denis
Souquet, Pierre Jean
Pignon, Jean-Pierre
Amour, Elodie
Celebic, Aljosa
Morin, Franck
Milleron, Bernard
Zalcman, Gerard
Soria, Jean-Charles
机构：
[1] Gustave Roussy, Villejuif, France
[2] CHU Toulouse, Hop Larrey, Toulouse, France
[3] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[4] Inst Cancerol Ouest, Nantes, France
[5] Inst Baclesse, Caen, France
[6] Ctr Hosp Pneumol Colmar, Colmar, France
[7] Hop Instruct Armes St Anne, Toulon, France
[8] Emile Muller Hosp, Mulhouse, France
[9] Le Mans Reg Hosp, Le Mans, France
[10] Grenoble Univ Hosp, Grenoble, France
[11] Lyon Sud Hosp, Acute Resp Med & Thorac Oncol Dept, Pierre Benite, France
[12] Lyon Univ, Inst Canc, Lyon Univ Hosp, Pierre Benite, France
[13] IFCT, Paris, France
[14] Inst Gustave Roussy, Villejuif, France
[15] Intergrp Francophone Cancerol Thorac, Paris, France
[16] Caen Univ Hosp, Caen, France
[17] Gustave Roussy Canc Campus, Drug Dev Dept, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7510
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
    Besse, B.
    Mazieres, J.
    Ribassin-Majed, L.
    Barlesi, F.
    Bennouna, J.
    Gervais, R.
    Moreau, L.
    Berard, H.
    Debieuvre, D.
    Molinier, O.
    Moro-Sibilot, D.
    Souquet, P. J.
    Jacquot, S.
    Petit, L.
    Lena, H.
    Pignon, J. P.
    Lacas, B.
    Morin, F.
    Milleron, B.
    Zalcman, G.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1078 - 1083
  • [2] ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP
    Besse, Benjamin
    Mazieres, Julien
    Ribassin-Majed, L.
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Debieuvre, Didier
    Molinier, Olivier
    Moro-Sibilot, Denis
    Souquet, Pierre-Jean
    Pignon, Jean-Pierre
    Amour, Elodie
    Celebic, A.
    Morin, Franck
    Milleron, Bernard
    Zalcman, Gerard
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S301 - S301
  • [3] Adjuvant pazopanib or placebo in resected stage I NSCLC patients: Results of the NSCLC adjuvant randomized phase II trial (IFCT0703) from the French collaborative Intergroup
    Besse, B.
    Mazieres, J.
    Pignon, J. P.
    Bennouna, J.
    Barlesi, F.
    Gervais, R.
    Amour, E.
    Morin, F.
    Zalcman, G.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S9 - S9
  • [4] Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
    Vasseur, Damien
    Jovelet, Cecile
    Cozic, Nathalie
    Mazieres, Julien
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Molinier, Olivier
    Moro-Sibilot, Denis
    Souquet, Pierre Jean
    Amour, Elodie
    Morin, Franck
    Zalcman, Gerard
    Soria, Jean-Charles
    Westeel, Virginie
    Lacroix, Ludovic
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] CORRELATION OF TUMOR VOLUME AND TUMOR MARKER INDEX (TMI) WITH SURVIVAL IN COMPLETELY RESECTED STAGE I/II NSCLC PATIENTS
    Muley, T.
    Fetz, H.
    Dienemann, H.
    Ebert, W.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3571 - 3571
  • [6] Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed and resected glioblastoma: Pazoglio trial.
    Saada-Bouzid, Esma
    Frenel, Jean-Sebastien
    Augereau, Paule
    Bourg, Veronique
    Gal, Jocelyn
    Jacquinot, Rique
    Gourmelon, Carole
    Chateau, Yann
    Barriere, Jerome
    Bondiau, Pierre-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS).
    von Mehren, Margaret
    Litwin, Samuel
    Ravi, Vinod
    Schuetze, Scott
    Movva, Sujana
    Agulnik, Mark
    Kraft, Andrew S.
    Tetzlaff, Eric Daniel
    Somaiah, Neeta
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Shen, Zi-Qing
    Feng, Kun-Peng
    Fang, Zi-Yao
    Xia, Tian
    Pan, Shu
    Ding, Cheng
    Xu, Chun
    Ju, Sheng
    Chen, Jun
    Li, Chang
    Zhao, Jun
    JOURNAL OF CARDIOTHORACIC SURGERY, 2024, 19 (01)
  • [9] Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Zi-Qing Shen
    Kun-Peng Feng
    Zi-Yao Fang
    Tian Xia
    Shu Pan
    Cheng Ding
    Chun Xu
    Sheng Ju
    Jun Chen
    Chang Li
    Jun Zhao
    Journal of Cardiothoracic Surgery, 19
  • [10] Increased tumor volume and tumor marker index (TMI) are negative predictors of outcome in completely resected stage I/II NSCLC patients
    不详
    ANTICANCER RESEARCH, 2005, 25 (6D) : 4803 - 4803
12345